Detalhe da pesquisa
1.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1075-86, 2015 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467591
2.
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Gastroenterology
; 147(1): 132-142.e4, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24704719
3.
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Antimicrob Agents Chemother
; 58(6): 3429-36, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24709256
4.
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
J Infect Dis
; 204(4): 601-8, 2011 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21791662
5.
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
J Hepatol
; 54(6): 1130-6, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21145848
6.
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Lancet Gastroenterol Hepatol
; 2(3): 177-188, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28404133
7.
Care-related pain and discomfort in children with motor disabilities in rehabilitation centres.
Ann Phys Rehabil Med
; 59(5-6): 314-319, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27315695
8.
The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial.
J Infect
; 67(4): 313-21, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23800784
9.
Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Antivir Ther
; 17(5): 927-32, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22611092